For more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 9:00 a.m. to 4:30 p.m. Deaf and hard-of-hearing callers with TTY equipment may call 1-800-332-8615. The call is free and a trained Cancer Information Specialist is available to answer your questions.
CHAT ONLINE
The NCI's LiveHelp® online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 9:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI Web sites and answer questions about cancer.
WRITE TO US
For more information from the NCI, please write to this address:
NCI Public Inquiries Office
Suite 3036A
6116 Executive Boulevard, MSC8322
Bethesda, MD 20892-8322
SEARCH THE NCI WEB SITE
The NCI Web site provides online access to information on cancer, clinical trials, and other Web sites and organizations that offer support and resources for cancer patients and their families. For a quick search, use our ?Best Bets? search box in the upper right hand corner of each Web page. The results that are most closely related to your search term will be listed as Best Bets at the top of the list of search results.
There are also many other places to get materials and information about cancer treatment and services. Hospitals in your area may have information about local and regional agencies that have information on finances, getting to and from treatment, receiving care at home, and dealing with problems related to cancer treatment.
FIND PUBLICATIONS
The NCI has booklets and other materials for patients, health professionals, and the public. These publications discuss types of cancer, methods of cancer treatment, coping with cancer, and clinical trials. Some publications provide information on tests for cancer, cancer causes and prevention, cancer statistics, and NCI research activities. NCI materials on these and other topics may be ordered online or printed directly from the NCI Publications Locator. These materials can also be ordered by telephone from the Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237), TTY at 1-800-332-8615.
Sunday, November 1, 2009
Changes to This Summary
The PDQcancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.
Changes were made to this summary to match those made to the health professional version.
Changes were made to this summary to match those made to the health professional version.
Questions or Comments About This Summary
If you have questions or comments about this summary, please send them to Cancer.gov through the Web site?s Contact Form. We can respond only to email messages written in English.
About PDQ
PDQ IS A COMPREHENSIVE CANCER DATABASE AVAILABLE ON NCI'S WEB SITE.
PDQ is the National Cancer Institute's (NCI's) comprehensive cancer information database. Most of the information contained in PDQ is available online at NCI's Web site. PDQ is provided as a service of the NCI. The NCI is part of the National Institutes of Health, the federal government's focal point for biomedical research.
PDQ CONTAINS CANCER INFORMATION SUMMARIES.
The PDQ database contains summaries of the latest published information on cancer prevention, detection, genetics, treatment, supportive care, and complementary and alternative medicine. Most summaries are available in two versions. The health professional versions provide detailed information written in technical language. The patient versions are written in easy-to-understand, nontechnical language. Both versions provide current and accurate cancer information.
THE PDQ CANCER INFORMATION SUMMARIES ARE DEVELOPED BY CANCER EXPERTS AND REVIEWED REGULARLY.
Editorial Boards made up of experts in oncology and related specialties are responsible for writing and maintaining the cancer information summaries. The summaries are reviewed regularly and changes are made as new information becomes available. The date on each summary ("Date Last Modified") indicates the time of the most recent change.
PDQ ALSO CONTAINS INFORMATION ON CLINICAL TRIALS.
A clinical trial is a study to answer a scientific question, such as whether one method of treating symptoms is better than another. Trials are based on past studies and what has been learned in the laboratory. Each trial answers certain scientific questions in order to find new and better ways to help cancer patients. Some patients have symptoms caused by cancer treatment or by the cancer itself. During supportive care clinical trials, information is collected about how well new ways to treat symptoms of cancer work. The trials also study side effects of treatment and problems that come up during or after treatment. If a clinical trial shows that a new treatment is better than one currently being used, the new treatment may become "standard." Patients who have symptoms related to cancer treatment may want to think about taking part in a clinical trial.
Listings of clinical trials are included in PDQ and are available online at NCI's Web site. Descriptions of the trials are available in health professional and patient versions. Many cancer doctors who take part in clinical trials are also listed in PDQ. For more information, call the Cancer Information Service 1-800-4-CANCER (1-800-422-6237); TTY at 1-800-332-8615.
PDQ is the National Cancer Institute's (NCI's) comprehensive cancer information database. Most of the information contained in PDQ is available online at NCI's Web site. PDQ is provided as a service of the NCI. The NCI is part of the National Institutes of Health, the federal government's focal point for biomedical research.
PDQ CONTAINS CANCER INFORMATION SUMMARIES.
The PDQ database contains summaries of the latest published information on cancer prevention, detection, genetics, treatment, supportive care, and complementary and alternative medicine. Most summaries are available in two versions. The health professional versions provide detailed information written in technical language. The patient versions are written in easy-to-understand, nontechnical language. Both versions provide current and accurate cancer information.
THE PDQ CANCER INFORMATION SUMMARIES ARE DEVELOPED BY CANCER EXPERTS AND REVIEWED REGULARLY.
Editorial Boards made up of experts in oncology and related specialties are responsible for writing and maintaining the cancer information summaries. The summaries are reviewed regularly and changes are made as new information becomes available. The date on each summary ("Date Last Modified") indicates the time of the most recent change.
PDQ ALSO CONTAINS INFORMATION ON CLINICAL TRIALS.
A clinical trial is a study to answer a scientific question, such as whether one method of treating symptoms is better than another. Trials are based on past studies and what has been learned in the laboratory. Each trial answers certain scientific questions in order to find new and better ways to help cancer patients. Some patients have symptoms caused by cancer treatment or by the cancer itself. During supportive care clinical trials, information is collected about how well new ways to treat symptoms of cancer work. The trials also study side effects of treatment and problems that come up during or after treatment. If a clinical trial shows that a new treatment is better than one currently being used, the new treatment may become "standard." Patients who have symptoms related to cancer treatment may want to think about taking part in a clinical trial.
Listings of clinical trials are included in PDQ and are available online at NCI's Web site. Descriptions of the trials are available in health professional and patient versions. Many cancer doctors who take part in clinical trials are also listed in PDQ. For more information, call the Cancer Information Service 1-800-4-CANCER (1-800-422-6237); TTY at 1-800-332-8615.
Spirituality in Cancer Care: Supportive care - Patient Information [NCI PDQ]
This information is produced and provided by the National Cancer Institute (NCI). The information in this topic may have changed since it was written. For the most current information, contact the National Cancer Institute via the Internet web site at
http://cancer.gov or call 1-800-4-CANCER
Spirituality in Cancer Care (PDQ®)
Overview
Many cancer patients rely on spiritual and/or religious beliefs and practices to help them cope with their disease. This is called spiritual coping. Studies have shown that female caregivers also commonly rely on spiritual coping. Some patients and their family-caregivers may want doctors to address spiritual concerns, but may feel unsure about how to bring up the subject. Patients may express their spiritual needs in different ways, depending on their cultural and religious traditions. Cancer professionals are looking at new ways to address these religious and spiritual concerns as part of overall quality of life. Medical staff may therefore ask patients to identify spiritual issues that are important to them, not only for end-of-life issues but also during treatment.
http://cancer.gov or call 1-800-4-CANCER
Spirituality in Cancer Care (PDQ®)
Overview
Many cancer patients rely on spiritual and/or religious beliefs and practices to help them cope with their disease. This is called spiritual coping. Studies have shown that female caregivers also commonly rely on spiritual coping. Some patients and their family-caregivers may want doctors to address spiritual concerns, but may feel unsure about how to bring up the subject. Patients may express their spiritual needs in different ways, depending on their cultural and religious traditions. Cancer professionals are looking at new ways to address these religious and spiritual concerns as part of overall quality of life. Medical staff may therefore ask patients to identify spiritual issues that are important to them, not only for end-of-life issues but also during treatment.
Applying for NFCR Research Funding
Cancer survival rates have significantly increased over the past three decades, mainly attributable to the development of more effective therapies and earlier diagnosis. This is the direct result of scientific breakthroughs derived from decades of innovative cancer research. As a leader in the cancer research community, NFCR has made essential contributions to the development of many of today’s most innovative and effective cancer therapies. In laboratories across the United States, Europe and Asia, NFCR scientists and their research groups are at the cutting-edge of cancer research today. What NFCR scientists have accomplished in cancer research is constantly being translated into improved prevention strategies, better detection methods, and more effective cancer therapies. From basic laboratory research to clinical application, research breakthroughs achieved by hundreds of dedicated NFCR scientists are making a difference in the lives of millions of cancer patients and their families today. Below is a list of select research breakthroughs made by NFCR-supported scientists since 1973.
What Is Cancer?
Newly Diagnosed
A new diagnosis of cancer can be a shock, making you feel out of control and overwhelmed. Getting informed can help alleviate these feelings. Remember, very few cancers require emergency treatment; you have time to learn about your diagnosis and treatment options, ask questions, and get a second opinion. This section is designed to help you address your initial questions before you move forward with your treatment.
What is Cancer?
Cancer is not one disease, but many diseases that occur in different areas of the body. Each type of cancer is characterized by the uncontrolled growth of cells. Under normal conditions, cell reproduction is carefully controlled by the body. However, these controls can malfunction, resulting in abnormal cell growth and the development of a lump, mass, or tumor. Some cancers involving the blood and blood-forming organs do not form tumors but circulate through other tissues where they grow.
A tumor may be benign (non-cancerous) or malignant (cancerous). Cells from cancerous tumors can spread throughout the body. This process, called metastasis, occurs when cancer cells break away from the original tumor and travel in the circulatory or lymphatic systems until they are lodged in a small capillary network in another area of the body. Common locations of metastasis are the bones, lungs, liver, and central nervous system.
The type of cancer refers to the organ or area of the body where the cancer first occurred. Cancer that has metastasized to other areas of the body is named for the part of the body where it originated. For example, if breast cancer has spread to the bones, it is called "metastatic breast cancer" not bone cancer.
How did I get cancer?
Although every patient and family member wants to know the answer to this question, the reason people develop cancer is not well understood. There are some known carcinogens (materials that can cause cancer), but many are still undiscovered. We do not know why some people who are exposed to carcinogens get cancer and others do not. The length and amount of exposure are believed to affect the chances of developing a disease. For example, as exposure to cigarette smoking increases, the chance of developing lung cancer also increases. Genetics also plays an important role in whether an individual develops cancer. For example, certain types of breast cancer have a genetic component.
What’s next?
Following your diagnosis of cancer, your reaction may be one of shock and disbelief. If you have been told that chemotherapy or radiation therapy are an important part of your treatment, many unpleasant images may come to mind. But as you move beyond that initial shock to begin the journey of surviving your cancer, you have many good reasons to be optimistic. Medicine has made—and continues to make—great strides in treating cancer and in making cancer treatment more tolerable, both physically and emotionally.
No one would call cancer a normal experience, but by proactively managing aspects of your treatment, you can maintain a sense of normalcy in your life. Fighting cancer is not a challenge you face alone. It's a team effort that involves family, friends, and your healthcare team. Don't overlook the strength that can come from having your support network by your side.
Diagnosing Cancer
A new diagnosis of cancer can be a shock, making you feel out of control and overwhelmed. Getting informed can help alleviate these feelings. Remember, very few cancers require emergency treatment; you have time to learn about your diagnosis and treatment options, ask questions, and get a second opinion. This section is designed to help you address your initial questions before you move forward with your treatment.
What is Cancer?
Cancer is not one disease, but many diseases that occur in different areas of the body. Each type of cancer is characterized by the uncontrolled growth of cells. Under normal conditions, cell reproduction is carefully controlled by the body. However, these controls can malfunction, resulting in abnormal cell growth and the development of a lump, mass, or tumor. Some cancers involving the blood and blood-forming organs do not form tumors but circulate through other tissues where they grow.
A tumor may be benign (non-cancerous) or malignant (cancerous). Cells from cancerous tumors can spread throughout the body. This process, called metastasis, occurs when cancer cells break away from the original tumor and travel in the circulatory or lymphatic systems until they are lodged in a small capillary network in another area of the body. Common locations of metastasis are the bones, lungs, liver, and central nervous system.
The type of cancer refers to the organ or area of the body where the cancer first occurred. Cancer that has metastasized to other areas of the body is named for the part of the body where it originated. For example, if breast cancer has spread to the bones, it is called "metastatic breast cancer" not bone cancer.
How did I get cancer?
Although every patient and family member wants to know the answer to this question, the reason people develop cancer is not well understood. There are some known carcinogens (materials that can cause cancer), but many are still undiscovered. We do not know why some people who are exposed to carcinogens get cancer and others do not. The length and amount of exposure are believed to affect the chances of developing a disease. For example, as exposure to cigarette smoking increases, the chance of developing lung cancer also increases. Genetics also plays an important role in whether an individual develops cancer. For example, certain types of breast cancer have a genetic component.
What’s next?
Following your diagnosis of cancer, your reaction may be one of shock and disbelief. If you have been told that chemotherapy or radiation therapy are an important part of your treatment, many unpleasant images may come to mind. But as you move beyond that initial shock to begin the journey of surviving your cancer, you have many good reasons to be optimistic. Medicine has made—and continues to make—great strides in treating cancer and in making cancer treatment more tolerable, both physically and emotionally.
No one would call cancer a normal experience, but by proactively managing aspects of your treatment, you can maintain a sense of normalcy in your life. Fighting cancer is not a challenge you face alone. It's a team effort that involves family, friends, and your healthcare team. Don't overlook the strength that can come from having your support network by your side.
Diagnosing Cancer
What is a cancer stage?
Following a diagnosis of cancer, the most important step is to accurately determine the stage of cancer. Stage describes how far the cancer has spread. (Some cancers, such as leukemia, may not be staged.) Each stage of cancer may be treated differently. In order for you to begin evaluating and discussing treatment options with your healthcare team, you need to know the correct stage of your cancer.
There are many staging systems, but TNM is the most common. “T” refers to the size of the tumor, “N” to the number of lymph nodes involved, and “M” to metastasis. TNM staging measures the extent of the disease by evaluating these three aspects and assigning a stage, which is usually between 0-4. Generally, the lower the stage, the better the treatment prognosis (outcome).
* Stage 0 – precancer
* Stage 1 – small cancer found only in the organ where it started
* Stage 2 – larger cancer that may or may not have spread to the lymph nodes
* Stage 3 – larger cancer that is also in the lymph nodes
* Stage 4 – cancer in a different organ from where it started
How is prognosis determined?
The probable course and/or outcome of the cancer is called the prognosis. Identifying factors that indicate a better or worse prognosis may help you and your doctor plan your treatment. There are many factors that help determine your prognosis. Some of these include:
* Your age
* Your level of physical fitness
* Size of your cancer
* Stage of your cancer
* Aggressiveness of your cancer (cancer cells that are growing and dividing rapidly are considered more aggressive)
Your doctor will evaluate all possible factors to determine your prognosis.
Recently, the genetic make-up of cancer is being increasingly recognized as an important prognostic factor. For example, some genes have been associated with an aggressive course or tendency to recur. Identification of these in an early stage cancer may indicate a poor prognosis. Some research suggests that the genetic make-up of the cancer may be even more important for determining prognosis than the stage of the cancer.
How is cancer diagnosed?
Diagnosing cancer involves the use of a variety of tests that provide details about abnormal cells, which may have been detected through routine medical examinations, self-examination, or reported symptoms. More information about these cells must be gathered in order to identify them as malignant (cancerous) or non-malignant (non-cancerous), and if they are malignant, to determine how serious (aggressive) the particular cancer cells are. Aggressive cancers grow and spread more quickly than less-aggressive or “indolent” cancers. There are many types of tests specifically designed to evaluate cancer:
* A pathology report is based on observation of abnormal cells under a microscope.
* Diagnostic imaging involves visualization of abnormal masses using high tech machines that create images, such as x-rays, computed tomography (CT), positron emission test (PET), magnetic resonance imaging (MRI), and combined PET/CT.
* Blood tests measure substances in the blood that may indicate how advanced the cancer is or other problems related to the cancer.
* Tumor marker tests detect substances in blood, urine, or other tissues that occur in higher than normal levels with certain cancers.
* Special laboratory evaluation of DNA involves the identification of the genetic make-up—the DNA—of the abnormal cells.
For more information about diagnostic tests, visit the Testing Center.
There are many staging systems, but TNM is the most common. “T” refers to the size of the tumor, “N” to the number of lymph nodes involved, and “M” to metastasis. TNM staging measures the extent of the disease by evaluating these three aspects and assigning a stage, which is usually between 0-4. Generally, the lower the stage, the better the treatment prognosis (outcome).
* Stage 0 – precancer
* Stage 1 – small cancer found only in the organ where it started
* Stage 2 – larger cancer that may or may not have spread to the lymph nodes
* Stage 3 – larger cancer that is also in the lymph nodes
* Stage 4 – cancer in a different organ from where it started
How is prognosis determined?
The probable course and/or outcome of the cancer is called the prognosis. Identifying factors that indicate a better or worse prognosis may help you and your doctor plan your treatment. There are many factors that help determine your prognosis. Some of these include:
* Your age
* Your level of physical fitness
* Size of your cancer
* Stage of your cancer
* Aggressiveness of your cancer (cancer cells that are growing and dividing rapidly are considered more aggressive)
Your doctor will evaluate all possible factors to determine your prognosis.
Recently, the genetic make-up of cancer is being increasingly recognized as an important prognostic factor. For example, some genes have been associated with an aggressive course or tendency to recur. Identification of these in an early stage cancer may indicate a poor prognosis. Some research suggests that the genetic make-up of the cancer may be even more important for determining prognosis than the stage of the cancer.
How is cancer diagnosed?
Diagnosing cancer involves the use of a variety of tests that provide details about abnormal cells, which may have been detected through routine medical examinations, self-examination, or reported symptoms. More information about these cells must be gathered in order to identify them as malignant (cancerous) or non-malignant (non-cancerous), and if they are malignant, to determine how serious (aggressive) the particular cancer cells are. Aggressive cancers grow and spread more quickly than less-aggressive or “indolent” cancers. There are many types of tests specifically designed to evaluate cancer:
* A pathology report is based on observation of abnormal cells under a microscope.
* Diagnostic imaging involves visualization of abnormal masses using high tech machines that create images, such as x-rays, computed tomography (CT), positron emission test (PET), magnetic resonance imaging (MRI), and combined PET/CT.
* Blood tests measure substances in the blood that may indicate how advanced the cancer is or other problems related to the cancer.
* Tumor marker tests detect substances in blood, urine, or other tissues that occur in higher than normal levels with certain cancers.
* Special laboratory evaluation of DNA involves the identification of the genetic make-up—the DNA—of the abnormal cells.
For more information about diagnostic tests, visit the Testing Center.
How does diagnosis determine treatment?
Historically, a combination of pathological assessment (laboratory evaluation using a microscope) and diagnostic imaging has been used to identify the type of cancer and its stage, and then the treatment. Stage indicates how extensive the cancer is and how much it has spread. Staging usually involves determining the size of the primary tumor and evaluating whether it has remained in the tissue in which it started, whether it has invaded other nearby organs or tissues, and whether cancer cells have spread to distant locations in the body. The cancer is then assigned a stage on a predetermined scale of numbers and letters, for example stage I, II, IIIa, IIIb, IV, etc. The higher number and letter combination indicates more extensive spread, and therefore a more serious condition. Treatment is often selected based on the stage of disease. Higher stage cancers typically receive very aggressive treatments and lower stage disease less aggressive treatment.
However, research has indicated that identifying the stage of disease may not be the most accurate technique for determining how aggressive it is. For example, some early stage diseases may recur or progress even after treatment, while some late stage cancers may stay in remission. These findings suggest that there may be factors other than how the cancer looks under a microscope and how far it has spread at the time of diagnosis that may better indicate the likelihood that a given cancer will recur and/or progress.
Human genomics, which is the study of the entire genetic material of humans, has provided invaluable tools for identifying the genetic components of cancers. The mapping of the human genome, which consists of 30,000 to 70,000 genes, has laid the ground work for understanding the role those genes play in human health and disease. Cancer is many different diseases; however, one aspect of all cancers that is similar is damage to the DNA resulting in uncontrolled cell growth. Identifying the genes for each cancer type that are involved in the capacity grow and spread may provide valuable prognostic information.
As improvements are made in the special laboratory techniques used to identify the genetic make-up of cancers, this genetic information may become a better predictor of cancer aggressiveness and outcome than stage, which has been the diagnostic indicator of choice in the past. Additionally, this genetic information will likely play an increasing role in directing treatment. Specifically, the genes involved in each cancer may indicate more aggressive treatment for some cancers and less aggressive treatment for others.
Introduction to Cancer Treatment
Overview of Cancer Treatments
Choice of cancer treatment is influenced by several factors, including the specific characteristics of your cancer; your overall condition; and whether the goal of treatment is to cure your cancer, keep your cancer from spreading, or to relieve the symptoms caused by cancer. Depending on these factors, you may receive one or more of the following:
* Surgery
* Chemotherapy
* Radiation therapy
* Hormonal therapy
* Targeted therapy
* Biological therapy
One or more treatment modalities may be used to provide you with the most effective treatment. Increasingly, it is common to use several treatment modalities together (concurrently) or in sequence with the goal of preventing recurrence. This is referred to as multi-modality treatment of the cancer.
However, research has indicated that identifying the stage of disease may not be the most accurate technique for determining how aggressive it is. For example, some early stage diseases may recur or progress even after treatment, while some late stage cancers may stay in remission. These findings suggest that there may be factors other than how the cancer looks under a microscope and how far it has spread at the time of diagnosis that may better indicate the likelihood that a given cancer will recur and/or progress.
Human genomics, which is the study of the entire genetic material of humans, has provided invaluable tools for identifying the genetic components of cancers. The mapping of the human genome, which consists of 30,000 to 70,000 genes, has laid the ground work for understanding the role those genes play in human health and disease. Cancer is many different diseases; however, one aspect of all cancers that is similar is damage to the DNA resulting in uncontrolled cell growth. Identifying the genes for each cancer type that are involved in the capacity grow and spread may provide valuable prognostic information.
As improvements are made in the special laboratory techniques used to identify the genetic make-up of cancers, this genetic information may become a better predictor of cancer aggressiveness and outcome than stage, which has been the diagnostic indicator of choice in the past. Additionally, this genetic information will likely play an increasing role in directing treatment. Specifically, the genes involved in each cancer may indicate more aggressive treatment for some cancers and less aggressive treatment for others.
Introduction to Cancer Treatment
Overview of Cancer Treatments
Choice of cancer treatment is influenced by several factors, including the specific characteristics of your cancer; your overall condition; and whether the goal of treatment is to cure your cancer, keep your cancer from spreading, or to relieve the symptoms caused by cancer. Depending on these factors, you may receive one or more of the following:
* Surgery
* Chemotherapy
* Radiation therapy
* Hormonal therapy
* Targeted therapy
* Biological therapy
One or more treatment modalities may be used to provide you with the most effective treatment. Increasingly, it is common to use several treatment modalities together (concurrently) or in sequence with the goal of preventing recurrence. This is referred to as multi-modality treatment of the cancer.
Chemotherapy
Chemotherapy is any treatment involving the use of drugs to kill cancer cells. Cancer chemotherapy may consist of single drugs or combinations of drugs, and can be administered through a vein, injected into a body cavity, or delivered orally in the form of a pill. Chemotherapy is different from surgery or radiation therapy in that the cancer-fighting drugs circulate in the blood to parts of the body where the cancer may have spread and can kill or eliminate cancers cells at sites great distances from the original cancer. As a result, chemotherapy is considered a systemic treatment.
More than half of all people diagnosed with cancer receive chemotherapy. For millions of people who have cancers that respond well to chemotherapy, this approach helps treat their cancer effectively, enabling them to enjoy full, productive lives. Furthermore, many side effects once associated with chemotherapy are now easily prevented or controlled, allowing many people to work, travel, and participate in many of their other normal activities while receiving chemotherapy.
More than half of all people diagnosed with cancer receive chemotherapy. For millions of people who have cancers that respond well to chemotherapy, this approach helps treat their cancer effectively, enabling them to enjoy full, productive lives. Furthermore, many side effects once associated with chemotherapy are now easily prevented or controlled, allowing many people to work, travel, and participate in many of their other normal activities while receiving chemotherapy.
Radiation Therapy
Radiation therapy, or radiotherapy, uses high-energy rays to damage or kill cancer cells by preventing them from growing and dividing. Similar to surgery, radiation therapy is a local treatment used to eliminate or eradicate visible tumors. Radiation therapy is not typically useful in eradicating cancer cells that have already spread to other parts of the body. Radiation therapy may be externally or internally delivered. External radiation delivers high-energy rays directly to the tumor site from a machine outside the body. Internal radiation, or brachytherapy, involves the implantation of a small amount of radioactive material in or near the cancer. Radiation may be used to cure or control cancer, or to ease some of the symptoms caused by cancer. Sometimes radiation is used with other types of cancer treatment, such as chemotherapy and surgery, and sometimes it is used alone.
Hormonal Therapy
Hormones are naturally occurring substances in the body that stimulate the growth of hormone sensitive tissues, such as the breast or prostate gland. When cancer arises in breast or prostate tissue, its growth and spread may be caused by the body’s own hormones. Therefore, drugs that block hormone production or change the way hormones work, and/or removal of organs that secrete hormones, such as the ovaries or testicles, are ways of fighting cancer. Hormone therapy, similar to chemotherapy, is a systemic treatment in that it may affect cancer cells throughout the body.
Targeted Therapy
A targeted therapy is one that is designed to treat only the cancer cells and minimize damage to normal, healthy cells. Cancer treatments that “target” cancer cells may offer the advantage of reduced treatment-related side effects and improved outcomes.
Conventional cancer treatments, such as chemotherapy and radiation therapy, cannot distinguish between cancer cells and healthy cells. Consequently, healthy cells are commonly damaged in the process of treating the cancer, which results in side effects. Chemotherapy damages rapidly dividing cells, a hallmark trait of cancer cells. In the process, healthy cells that are also rapidly dividing, such as blood cells and the cells lining the mouth and GI tract are also damaged. Radiation therapy kills some healthy cells that are in the path of the radiation or near the cancer being treated. Newer radiation therapy techniques can reduce, but not eliminate this damage. Treatment-related damage to healthy cells leads to complications of treatment, or side effects. These side effects may be severe, reducing a patient's quality of life, compromising their ability to receive their full, prescribed treatment, and sometimes, limiting their chance for an optimal outcome from treatment.
Conventional cancer treatments, such as chemotherapy and radiation therapy, cannot distinguish between cancer cells and healthy cells. Consequently, healthy cells are commonly damaged in the process of treating the cancer, which results in side effects. Chemotherapy damages rapidly dividing cells, a hallmark trait of cancer cells. In the process, healthy cells that are also rapidly dividing, such as blood cells and the cells lining the mouth and GI tract are also damaged. Radiation therapy kills some healthy cells that are in the path of the radiation or near the cancer being treated. Newer radiation therapy techniques can reduce, but not eliminate this damage. Treatment-related damage to healthy cells leads to complications of treatment, or side effects. These side effects may be severe, reducing a patient's quality of life, compromising their ability to receive their full, prescribed treatment, and sometimes, limiting their chance for an optimal outcome from treatment.
Biological Therapy
Biological therapy is referred to by many terms, including immunologic therapy, immunotherapy, or biotherapy. Biological therapy is a type of treatment that uses the body’s immune system to facilitate the killing of cancer cells. Types of biological therapy include interferon, interleukin, monoclonal antibodies, colony stimulating factors (cytokines), and vaccines.
Personalized Cancer Care
There is no longer a “one-size-fits-all” approach to cancer treatment. Even among patients with the same type of cancer, the behavior of the cancer and its response to treatment can vary widely. By exploring the reasons for this variation, researchers have begun to pave the way for more personalized cancer treatment. It is becoming increasingly clear that specific characteristics of cancer cells and cancer patients can have a profound impact on prognosis and treatment outcome. Although factoring these characteristics into treatment decisions makes cancer care more complex, it also offers the promise of improved outcomes.
The idea of matching a particular treatment to a particular patient is not a new one. It has long been recognized, for example, that hormonal therapy for breast cancer is most likely to be effective when the breast cancer contains receptors for estrogen and/or progesterone. Testing for these receptors is part of the standard clinical work-up of breast cancer. What is new, however, is the pace at which researchers are identifying new tumor markers, new tests, and new and more targeted drugs that individualize cancer treatment. Tests now exist that can assess the likelihood of cancer recurrence, the likelihood of response to particular drugs, and the presence of specific cancer targets that can be attacked by new anti-cancer drugs that directly target individual cancer cells.
To learn more about personalized cancer care for two common types of cancer, visit the following:
* Breast Cancer
* Colon Cancer
The idea of matching a particular treatment to a particular patient is not a new one. It has long been recognized, for example, that hormonal therapy for breast cancer is most likely to be effective when the breast cancer contains receptors for estrogen and/or progesterone. Testing for these receptors is part of the standard clinical work-up of breast cancer. What is new, however, is the pace at which researchers are identifying new tumor markers, new tests, and new and more targeted drugs that individualize cancer treatment. Tests now exist that can assess the likelihood of cancer recurrence, the likelihood of response to particular drugs, and the presence of specific cancer targets that can be attacked by new anti-cancer drugs that directly target individual cancer cells.
To learn more about personalized cancer care for two common types of cancer, visit the following:
* Breast Cancer
* Colon Cancer
Breast Cancer
Breast cancer is a common malignancy, with ~180,000 new cases diagnosed in the United States each year.[1] The disease occurs most frequently in women and rarely, in men. The breasts are glands that produce and release milk in women in association with pregnancy. Breast cancer develops from cells in the breast.
The normal breast has 6 to 9 overlapping sections called lobes and within each lobe are several smaller lobules that contain the cells that produce milk. The lobes and lobules are linked by thin tubes called ducts, which lead to the nipple in the center of the breast. The spaces around the lobules and ducts are filled with fat. Lymph vessels carry colorless fluid called lymph, which contains important immune cells. The lymph vessels lead to small bean-shaped structures called lymph nodes. Clusters of lymph nodes are found in the axilla (under the arm), above the collarbone, and in the chest.
The suspicion of breast cancer first arises when a lump is detected in the breast during breast examination or a suspicious area is identified during screening mammography. In order to diagnose the cause of the suspicious area or lump in the breast, a physician will perform a biopsy. A biopsy can be performed on an outpatient basis. During a biopsy, a physician removes cells for examination in the laboratory to determine whether cancer is present. Other information obtained from the biopsy sample will play an important role in treatment decisions. If the biopsy indicates that cancer is present, additional surgery may be performed after the patient and doctor select a course of treatment.
There are many types of breast tumors. Some breast tumors are benign (not cancerous). Benign breast tumors such as fibroadenomas or papillomas do not spread outside of the breast and are not life threatening. Other breast tumors are malignant (cancerous). The most common type of breast cancer is called ductal carcinoma and begins in the lining of the ducts. Another type of cancer is called lobular carcinoma, which arises in the lobules.
Personalized Cancer Care Center
When cancer is identified in the biopsy specimen, several other tests may be performed on the specimen in order to further classify the cancer and determine the optimal treatment strategy. Based on the stage of the cancer and the results of these tests, treatment of breast cancer is personalized for each individual. Treatment may involve surgery, radiation therapy, chemotherapy, targeted therapy, and/or hormonal therapy.
Stage: Stage is a measure of the extent of the cancer, and is based on the size of the tumor and the presence or absence of lymph node metastases and distant metastases. Determining the stage of the cancer may require a number of procedures, such as blood tests, chest x-rays, mammography, computed tomography (CT), or magnetic resonance imaging (MRI). For patients with early-stage cancer, the spread of the cancer to the axillary (under the arm) lymph nodes may be assessed through either sentinel lymph node biopsy or axillary lymph node dissection. Axillary lymph node dissection involves the removal of many axillary lymph nodes; the procedure can be associated with chronic side effects such as pain, limited shoulder motion, numbness, and swelling. Sentinel lymph node biopsy is a more recent procedure that involves the removal of only a small number of nodes, or even a single node. If the sentinel lymph nodes are negative (show no evidence of cancer), then no further lymph node surgery is required. Sentinel lymph node biopsy is becoming more widely adopted in the clinical setting for determining whether cancer has spread to the lymph nodes in women with localized breast cancer.
HER2 status: Twenty to thirty percent of breast cancers overexpress (make too much of) a protein known as HER2. Overexpression of this protein leads to increased growth of cancer cells. Fortunately, the development of treatments that specifically target HER2-positive cells – such as Herceptin® (trastuzumab) and Tykerb® (lapatinib) -- has improved outcomes among women with HER2-positive breast cancer. For this reason, HER2 status should be accurately measured on all breast cancers.
Hormone receptor status: Some breast cancer cells express an abundance of receptors for the female hormones estrogen and/or progesterone. These cancers-- called hormone receptor-positive --are typically associated with a better prognosis and are treated differently from breast cancers that are hormone receptor-negative. Patients with hormone receptor-positive breast cancer often receive treatment with hormonal therapy, such as tamoxifen or an aromatase inhibitor. For more information, go to Hormonal Therapy.
Predicting the need for chemotherapy: Among women with early-stage breast cancer, the expression, or activity, of certain genes has been linked with the likelihood of cancer recurrence and chemotherapy benefit; testing tumor tissue for the expression of these genes can provide important information about prognosis and likely response to treatment.
A genomic test that is included in guidelines from both the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) is Oncotype DX®. Based on the expression of 21 genes, this test provides information about recurrence risk and likely chemotherapy benefit among women with newly diagnosed breast cancer that has not spread to the lymph nodes (node-negative) and is hormone receptor-positive. Oncotype DX has also shown promising results in women with node-positive breast cancer.[2]
For more information about OncotypeDX, visit http://www.mytreatmentdecision.com/
Predicting drug metabolism: Another type of test that may prove important is the assessment of inherited genetic variation that influences drug metabolism (the processing of drugs by the body). In the case of tamoxifen, for example, differences in effectiveness may be explained at least in part by inherited differences in a gene known as CYP2D6.[3] Most people have two functional versions of this gene and are able to effectively process tamoxifen. Some people, however, have versions of this gene that are less effective at processing tamoxifen. Testing patients for these gene variants could help doctors identify patients who are less likely to respond to tamoxifen. A currently available test is AmpliChip®, which assesses CYP2D6 as well as CYP2C19 (another gene involved in drug metabolism). Additional data are required, however, before formal recommendations can be developed about this type of testing.[4]
For more information about AmpliChip, visit http://www.amplichip.us/.
Learn More
Patients who have already undergone surgery and lymph node evaluation and know their stage of cancer may select from the options below. In order to learn more about surgery and sentinel lymph node dissection, go to Surgery for Breast Cancer.
Carcinoma In Situ: Approximately 15-20% of breast cancers are very early in their development. These are sometimes referred to as carcinoma in situ and consist of two types: ductal carcinoma in situ (DCIS), which originates in the ducts and lobular carcinoma in situ (LCIS), which originates in the lobules. DCIS is the precursor to invasive cancer and LCIS is a risk factor for developing cancer.
Stage I: Cancer is confined to a single site in the breast, is less than 2 centimeters (3/4 inch) in size and has not spread outside the breast.
Stage IIA: Cancer has spread to involve underarm lymph nodes and is less than 2 centimeters (3/4 inch) in size or the primary cancer itself is 2-5 centimeters (3/4-2 inches) and has not spread to the lymph nodes.
Stage IIB: Cancer has spread to involve underarm lymph nodes and/or the primary cancer is greater than 5 centimeters (2 inches) in size and does not involve any lymph nodes.
Stage IIIA: Cancer is smaller than 5 centimeters (2 inches) and has spread to the lymph nodes under the arm or the lymph nodes are attached to each other or to other structures or the primary cancer is larger than 5 centimeters (2 inches) and has spread to the lymph nodes under the arm.
Stage IIIB: Cancer directly involves the chest wall or has spread to internal lymph nodes on the same side of the chest.
Inflammatory: Inflammatory breast cancer is a special class of breast cancer that is rare. The breast looks as if it is inflamed because of its red appearance and warmth. The skin may show signs of ridges and wheals or it may have a pitted appearance. Inflammatory breast cancer tends to spread quickly.
Stage IV: Cancer has spread to distant locations in the body, which may include the liver, lungs, bones or other sites.
Recurrent/Relapsed: The breast cancer has progressed or returned (recurred/relapsed) following an initial treatment.
The normal breast has 6 to 9 overlapping sections called lobes and within each lobe are several smaller lobules that contain the cells that produce milk. The lobes and lobules are linked by thin tubes called ducts, which lead to the nipple in the center of the breast. The spaces around the lobules and ducts are filled with fat. Lymph vessels carry colorless fluid called lymph, which contains important immune cells. The lymph vessels lead to small bean-shaped structures called lymph nodes. Clusters of lymph nodes are found in the axilla (under the arm), above the collarbone, and in the chest.
The suspicion of breast cancer first arises when a lump is detected in the breast during breast examination or a suspicious area is identified during screening mammography. In order to diagnose the cause of the suspicious area or lump in the breast, a physician will perform a biopsy. A biopsy can be performed on an outpatient basis. During a biopsy, a physician removes cells for examination in the laboratory to determine whether cancer is present. Other information obtained from the biopsy sample will play an important role in treatment decisions. If the biopsy indicates that cancer is present, additional surgery may be performed after the patient and doctor select a course of treatment.
There are many types of breast tumors. Some breast tumors are benign (not cancerous). Benign breast tumors such as fibroadenomas or papillomas do not spread outside of the breast and are not life threatening. Other breast tumors are malignant (cancerous). The most common type of breast cancer is called ductal carcinoma and begins in the lining of the ducts. Another type of cancer is called lobular carcinoma, which arises in the lobules.
Personalized Cancer Care Center
When cancer is identified in the biopsy specimen, several other tests may be performed on the specimen in order to further classify the cancer and determine the optimal treatment strategy. Based on the stage of the cancer and the results of these tests, treatment of breast cancer is personalized for each individual. Treatment may involve surgery, radiation therapy, chemotherapy, targeted therapy, and/or hormonal therapy.
Stage: Stage is a measure of the extent of the cancer, and is based on the size of the tumor and the presence or absence of lymph node metastases and distant metastases. Determining the stage of the cancer may require a number of procedures, such as blood tests, chest x-rays, mammography, computed tomography (CT), or magnetic resonance imaging (MRI). For patients with early-stage cancer, the spread of the cancer to the axillary (under the arm) lymph nodes may be assessed through either sentinel lymph node biopsy or axillary lymph node dissection. Axillary lymph node dissection involves the removal of many axillary lymph nodes; the procedure can be associated with chronic side effects such as pain, limited shoulder motion, numbness, and swelling. Sentinel lymph node biopsy is a more recent procedure that involves the removal of only a small number of nodes, or even a single node. If the sentinel lymph nodes are negative (show no evidence of cancer), then no further lymph node surgery is required. Sentinel lymph node biopsy is becoming more widely adopted in the clinical setting for determining whether cancer has spread to the lymph nodes in women with localized breast cancer.
HER2 status: Twenty to thirty percent of breast cancers overexpress (make too much of) a protein known as HER2. Overexpression of this protein leads to increased growth of cancer cells. Fortunately, the development of treatments that specifically target HER2-positive cells – such as Herceptin® (trastuzumab) and Tykerb® (lapatinib) -- has improved outcomes among women with HER2-positive breast cancer. For this reason, HER2 status should be accurately measured on all breast cancers.
Hormone receptor status: Some breast cancer cells express an abundance of receptors for the female hormones estrogen and/or progesterone. These cancers-- called hormone receptor-positive --are typically associated with a better prognosis and are treated differently from breast cancers that are hormone receptor-negative. Patients with hormone receptor-positive breast cancer often receive treatment with hormonal therapy, such as tamoxifen or an aromatase inhibitor. For more information, go to Hormonal Therapy.
Predicting the need for chemotherapy: Among women with early-stage breast cancer, the expression, or activity, of certain genes has been linked with the likelihood of cancer recurrence and chemotherapy benefit; testing tumor tissue for the expression of these genes can provide important information about prognosis and likely response to treatment.
A genomic test that is included in guidelines from both the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) is Oncotype DX®. Based on the expression of 21 genes, this test provides information about recurrence risk and likely chemotherapy benefit among women with newly diagnosed breast cancer that has not spread to the lymph nodes (node-negative) and is hormone receptor-positive. Oncotype DX has also shown promising results in women with node-positive breast cancer.[2]
For more information about OncotypeDX, visit http://www.mytreatmentdecision.com/
Predicting drug metabolism: Another type of test that may prove important is the assessment of inherited genetic variation that influences drug metabolism (the processing of drugs by the body). In the case of tamoxifen, for example, differences in effectiveness may be explained at least in part by inherited differences in a gene known as CYP2D6.[3] Most people have two functional versions of this gene and are able to effectively process tamoxifen. Some people, however, have versions of this gene that are less effective at processing tamoxifen. Testing patients for these gene variants could help doctors identify patients who are less likely to respond to tamoxifen. A currently available test is AmpliChip®, which assesses CYP2D6 as well as CYP2C19 (another gene involved in drug metabolism). Additional data are required, however, before formal recommendations can be developed about this type of testing.[4]
For more information about AmpliChip, visit http://www.amplichip.us/.
Learn More
Patients who have already undergone surgery and lymph node evaluation and know their stage of cancer may select from the options below. In order to learn more about surgery and sentinel lymph node dissection, go to Surgery for Breast Cancer.
Carcinoma In Situ: Approximately 15-20% of breast cancers are very early in their development. These are sometimes referred to as carcinoma in situ and consist of two types: ductal carcinoma in situ (DCIS), which originates in the ducts and lobular carcinoma in situ (LCIS), which originates in the lobules. DCIS is the precursor to invasive cancer and LCIS is a risk factor for developing cancer.
Stage I: Cancer is confined to a single site in the breast, is less than 2 centimeters (3/4 inch) in size and has not spread outside the breast.
Stage IIA: Cancer has spread to involve underarm lymph nodes and is less than 2 centimeters (3/4 inch) in size or the primary cancer itself is 2-5 centimeters (3/4-2 inches) and has not spread to the lymph nodes.
Stage IIB: Cancer has spread to involve underarm lymph nodes and/or the primary cancer is greater than 5 centimeters (2 inches) in size and does not involve any lymph nodes.
Stage IIIA: Cancer is smaller than 5 centimeters (2 inches) and has spread to the lymph nodes under the arm or the lymph nodes are attached to each other or to other structures or the primary cancer is larger than 5 centimeters (2 inches) and has spread to the lymph nodes under the arm.
Stage IIIB: Cancer directly involves the chest wall or has spread to internal lymph nodes on the same side of the chest.
Inflammatory: Inflammatory breast cancer is a special class of breast cancer that is rare. The breast looks as if it is inflamed because of its red appearance and warmth. The skin may show signs of ridges and wheals or it may have a pitted appearance. Inflammatory breast cancer tends to spread quickly.
Stage IV: Cancer has spread to distant locations in the body, which may include the liver, lungs, bones or other sites.
Recurrent/Relapsed: The breast cancer has progressed or returned (recurred/relapsed) following an initial treatment.
Colon Cancer
The colon and rectum are parts of the body's digestive system and together form a long, muscular tube called the large intestine. The colon is the first 6 feet of the large intestine and the rectum is the last 8-10 inches. Treatment approaches differ between cancers of the colon or rectum and are, therefore, discussed separately. A separate section has been created for Rectal Cancer.
Adenocarcinoma refers to cancer that begins in the cells that line the colon or large intestine and accounts for over 90%-95% of cancers originating in the colon. Other cancers, including carcinoid tumors and leiomyosarcoma, also originate in the colon, but are not referred to as colon cancer. This treatment overview deals only with adenocarcinoma of the colon, which will be referred to as colon cancer.
The treatment of colon cancer typically consists of surgery and/or chemotherapy and may involve several physicians, including a gastroenterologist, a surgeon, a medical oncologist and other specialists. Care must be carefully coordinated between the various treating physicians involved in managing the cancer.
Colon cancer begins in cells that line the colon. As the cells increase in number, they spread circumferentially around the colon like a "napkin ring." If detected early, cancer cells may only be found in the colon. If not detected early, the cancer may invade adjacent organs and spread through the lymph and blood systems throughout the body to the liver, lungs and other organs.
Personalized Cancer Care Center
After colon cancer has been diagnosed, tests will be performed to determine the extent and characteristics of the cancer. Based on these tests, treatment of colon cancer is personalized for each individual.
Adenocarcinoma refers to cancer that begins in the cells that line the colon or large intestine and accounts for over 90%-95% of cancers originating in the colon. Other cancers, including carcinoid tumors and leiomyosarcoma, also originate in the colon, but are not referred to as colon cancer. This treatment overview deals only with adenocarcinoma of the colon, which will be referred to as colon cancer.
The treatment of colon cancer typically consists of surgery and/or chemotherapy and may involve several physicians, including a gastroenterologist, a surgeon, a medical oncologist and other specialists. Care must be carefully coordinated between the various treating physicians involved in managing the cancer.
Colon cancer begins in cells that line the colon. As the cells increase in number, they spread circumferentially around the colon like a "napkin ring." If detected early, cancer cells may only be found in the colon. If not detected early, the cancer may invade adjacent organs and spread through the lymph and blood systems throughout the body to the liver, lungs and other organs.
Personalized Cancer Care Center
After colon cancer has been diagnosed, tests will be performed to determine the extent and characteristics of the cancer. Based on these tests, treatment of colon cancer is personalized for each individual.
Personalized Cancer Care Center
After colon cancer has been diagnosed, tests will be performed to determine the extent and characteristics of the cancer. Based on these tests, treatment of colon cancer is personalized for each individual.
Staging
Determining the stage of the cancer or the extent of the spread requires a number of tests and is ultimately confirmed by surgical removal of the cancer and exploration of the abdominal cavity. The following tests may be used to look for cancer in the chest, abdomen and pelvis.
Computed Tomography (CT) Scan:
A CT scan is a technique for imaging body tissues and organs, during which X-ray transmissions are converted to detailed images, using a computer to synthesize X-ray data. A CT scan is conducted with a large machine positioned outside the body that can rotate to capture detailed images of the organs and tissues inside the body. This method is more sensitive and precise than an X-ray.
Magnetic Resonance Imaging (MRI):
MRI uses a magnetic field rather than X-rays, and can often distinguish more accurately between healthy and diseased tissue. MRI gives better pictures of tumors located near bone than CT, does not use radiation as CT does, and provides pictures from various angles that enable doctors to construct a three-dimensional image of the tumor.
Colonoscopy:
Because 3-5% of patients with a colon cancer can already have an additional cancer in their colon, colonoscopy is routinely recommended to identify whether a second cancer is present in the colon prior to surgery. During a colonoscopy, a long flexible tube that is attached to a camera is inserted through the rectum, allowing physicians to examine the internal lining of the colon for polyps or other abnormalities. Patients are given medication to minimize discomfort. The physician may perform a biopsy in order to collect samples of suspicious tissues or cells for closer examination.
Ultrasound:
Ultrasound is a technique that uses sound waves to differentiate tissues based on varying tissue density. Ultrasound can be used transdermally (through the skin), transrectally (using a small probe inserted into the rectum) or intraoperatively (during surgery or during colonoscopy, which is called endoscopic ultrasound). Transrectal or endoscopic ultrasound may be used in conjunction with CT or MRI scans to help with staging.
Staging
Determining the stage of the cancer or the extent of the spread requires a number of tests and is ultimately confirmed by surgical removal of the cancer and exploration of the abdominal cavity. The following tests may be used to look for cancer in the chest, abdomen and pelvis.
Computed Tomography (CT) Scan:
A CT scan is a technique for imaging body tissues and organs, during which X-ray transmissions are converted to detailed images, using a computer to synthesize X-ray data. A CT scan is conducted with a large machine positioned outside the body that can rotate to capture detailed images of the organs and tissues inside the body. This method is more sensitive and precise than an X-ray.
Magnetic Resonance Imaging (MRI):
MRI uses a magnetic field rather than X-rays, and can often distinguish more accurately between healthy and diseased tissue. MRI gives better pictures of tumors located near bone than CT, does not use radiation as CT does, and provides pictures from various angles that enable doctors to construct a three-dimensional image of the tumor.
Colonoscopy:
Because 3-5% of patients with a colon cancer can already have an additional cancer in their colon, colonoscopy is routinely recommended to identify whether a second cancer is present in the colon prior to surgery. During a colonoscopy, a long flexible tube that is attached to a camera is inserted through the rectum, allowing physicians to examine the internal lining of the colon for polyps or other abnormalities. Patients are given medication to minimize discomfort. The physician may perform a biopsy in order to collect samples of suspicious tissues or cells for closer examination.
Ultrasound:
Ultrasound is a technique that uses sound waves to differentiate tissues based on varying tissue density. Ultrasound can be used transdermally (through the skin), transrectally (using a small probe inserted into the rectum) or intraoperatively (during surgery or during colonoscopy, which is called endoscopic ultrasound). Transrectal or endoscopic ultrasound may be used in conjunction with CT or MRI scans to help with staging.
Upon completion of the clinical staging evaluation, surgery is performed to remove the cancer along with part of the normal adjacent colon and determi
Upon completion of the clinical staging evaluation, surgery is performed to remove the cancer along with part of the normal adjacent colon and determine the level of spread within the colon and abdomen. Surgery is performed through an abdominal incision or through a laparoscope. Laparoscopic surgery is less invasive and involves the insertion of surgical instruments through very small incisions in the abdomen. Patients experience faster healing times compared with traditional abdominal surgery, and their outcomes with regard to cancer recurrence and survival have been shown in some trials to be similar.[1] It is important for patients to discuss the risks and benefits of the two techniques with their doctor, as laparoscopic surgery is not yet the standard of care, but is still considered investigational.
Following surgical removal of colon cancer and examination of removed tissue under a microscope, a final "pathologic" stage will be given.
KRAS Testing
For patients with metastatic colon cancer (cancer that has spread to distant sites in the body), a sample of the cancer may be tested for mutations in the KRAS gene.[2] Cancers that contain KRAS mutations are unlikely to respond to two targeted therapies that may be used in the treatment of metastatic colorectal cancer: Erbitux® (cetuximab)[3] and Vectibix® (panitumumab).[4]
All treatment information concerning colon cancer is categorized and discussed by the stage. In order to learn more about the most recent information available concerning the treatment of colon cancer, click on the appropriate stage.
Stage I: Cancer is confined to the lining of the colon.
Stage II: Cancer may penetrate the wall of the colon into the abdominal cavity or other adjacent organs but does not invade any local lymph nodes.
Stage III: Cancer invades one or more of the local lymph nodes but has not spread to other distant organs.
Stage IV: Cancer has spread to distant locations in the body, which may include the liver, lungs, bones or other sites.
Recurrent/Relapsed: Colon cancer has progressed or returned (recurred/relapsed) following initial treatment.
Following surgical removal of colon cancer and examination of removed tissue under a microscope, a final "pathologic" stage will be given.
KRAS Testing
For patients with metastatic colon cancer (cancer that has spread to distant sites in the body), a sample of the cancer may be tested for mutations in the KRAS gene.[2] Cancers that contain KRAS mutations are unlikely to respond to two targeted therapies that may be used in the treatment of metastatic colorectal cancer: Erbitux® (cetuximab)[3] and Vectibix® (panitumumab).[4]
All treatment information concerning colon cancer is categorized and discussed by the stage. In order to learn more about the most recent information available concerning the treatment of colon cancer, click on the appropriate stage.
Stage I: Cancer is confined to the lining of the colon.
Stage II: Cancer may penetrate the wall of the colon into the abdominal cavity or other adjacent organs but does not invade any local lymph nodes.
Stage III: Cancer invades one or more of the local lymph nodes but has not spread to other distant organs.
Stage IV: Cancer has spread to distant locations in the body, which may include the liver, lungs, bones or other sites.
Recurrent/Relapsed: Colon cancer has progressed or returned (recurred/relapsed) following initial treatment.
Surgery
Upon completion of the clinical staging evaluation, surgery is performed to remove the cancer along with part of the normal adjacent colon and determine the level of spread within the colon and abdomen. Surgery is performed through an abdominal incision or through a laparoscope. Laparoscopic surgery is less invasive and involves the insertion of surgical instruments through very small incisions in the abdomen. Patients experience faster healing times compared with traditional abdominal surgery, and their outcomes with regard to cancer recurrence and survival have been shown in some trials to be similar.[1] It is important for patients to discuss the risks and benefits of the two techniques with their doctor, as laparoscopic surgery is not yet the standard of care, but is still considered investigational.
Following surgical removal of colon cancer and examination of removed tissue under a microscope, a final "pathologic" stage will be given.
KRAS Testing
For patients with metastatic colon cancer (cancer that has spread to distant sites in the body), a sample of the cancer may be tested for mutations in the KRAS gene.[2] Cancers that contain KRAS mutations are unlikely to respond to two targeted therapies that may be used in the treatment of metastatic colorectal cancer: Erbitux® (cetuximab)[3] and Vectibix® (panitumumab).[4]
All treatment information concerning colon cancer is categorized and discussed by the stage. In order to learn more about the most recent information available concerning the treatment of colon cancer, click on the appropriate stage.
Stage I: Cancer is confined to the lining of the colon.
Stage II: Cancer may penetrate the wall of the colon into the abdominal cavity or other adjacent organs but does not invade any local lymph nodes.
Stage III: Cancer invades one or more of the local lymph nodes but has not spread to other distant organs.
Stage IV: Cancer has spread to distant locations in the body, which may include the liver, lungs, bones or other sites.
Recurrent/Relapsed: Colon cancer has progressed or returned (recurred/relapsed) following initial treatment.
Following surgical removal of colon cancer and examination of removed tissue under a microscope, a final "pathologic" stage will be given.
KRAS Testing
For patients with metastatic colon cancer (cancer that has spread to distant sites in the body), a sample of the cancer may be tested for mutations in the KRAS gene.[2] Cancers that contain KRAS mutations are unlikely to respond to two targeted therapies that may be used in the treatment of metastatic colorectal cancer: Erbitux® (cetuximab)[3] and Vectibix® (panitumumab).[4]
All treatment information concerning colon cancer is categorized and discussed by the stage. In order to learn more about the most recent information available concerning the treatment of colon cancer, click on the appropriate stage.
Stage I: Cancer is confined to the lining of the colon.
Stage II: Cancer may penetrate the wall of the colon into the abdominal cavity or other adjacent organs but does not invade any local lymph nodes.
Stage III: Cancer invades one or more of the local lymph nodes but has not spread to other distant organs.
Stage IV: Cancer has spread to distant locations in the body, which may include the liver, lungs, bones or other sites.
Recurrent/Relapsed: Colon cancer has progressed or returned (recurred/relapsed) following initial treatment.
Subscribe to:
Posts (Atom)
